Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Fungicide sales were up 0.5% as volume recovery slightly outweighed a decline in prices ... that Bayer’s HealthCare unit co-develops Eylea with Regeneron REGN, which records net product ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks ...

The MERLIN study was comparing Beovu to Eylea ... drug's sales momentum if approved. Filings are due before the end of the year. Bayer's CEO says new product launches will offset the decline ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion in ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Despite the challenges related to the EYLEA product line, the analyst views potential in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s long-term growth prospects. Furthermore, the Factor XI ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...